arrow
A

Aristotelis Bamias

National and Kapodistrian University of Athens
H指数:60
被引数:1.8万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Cabozantinib After Immunotherapy in Advanced Renal Cell Carcinoma. The CARE Study by the Hellenic Gu Cancer Group

免疫疗法后使用卡博扎替尼治疗晚期肾细胞癌。希腊GU癌症小组的CARE研究

2026-09-170
OA
Machine learning integrated explainable artificial intelligence in predicting toxicities of enfortumab vedotin in urothelial carcinoma: an exploratory study

机器学习集成可解释人工智能在预测恩福妥单抗维多汀在尿路上皮癌毒性中的作用:一项探索性研究

2026-09-160
PRE
Baseline Disease Characteristics and Platinum Sensitivity as Predictors of Outcomes in Sequential Therapy with Platinum-Based Chemotherapy, Avelumab Maintenance, and Enfortumab Vedotin in Advanced Urothelial Carcinoma (ARON-2EV Study)

基线疾病特征和铂类药物敏感性作为顺铂为基础化疗、阿维鲁姆单抗维持治疗和恩沃利单抗维多汀序贯疗法在晚期尿路上皮癌中的预后预测因素(ARON-2EV研究)

2026-07-290
PRE
Immunotherapy for Upper Tract Urothelial Carcinomas: A 2026 Update

上尿路尿路上皮癌的免疫治疗:2026年更新

Cancers
IF4.4
2026-05-190
OAAI
Adjuvant nivolumab versus placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274

高风险肌层浸润性尿路上皮癌的辅助尼洛替尼对比安慰剂:CheckMate 274研究的5年疗效和ctDNA结果

2025-10-170
OAAI
Lean mass as a key determinant of bone density in primary hyperparathyroidism: insights from dual-energy x-ray absorptiometry (DXA)-derived body composition analysis

瘦体质量作为原发性甲状旁腺功能亢进症中骨密度的关键决定因素:双能X射线吸收测定法(DXA)衍生体成分分析的见解

2025-09-010
OA
Nivolumab plus cabozantinib in metastatic renal cell carcinoma: real-world evidence from the international ARON-1 study

纳武利尤单抗联合卡博替尼治疗转移性肾细胞癌:国际ARON-1研究的真实世界证据

2025-07-270
OA
Current status of adjuvant immunotherapy and relapse management in renal cell carcinoma: Insights from a European delphi study

肾细胞癌辅助免疫治疗和复发管理的现状:欧洲德尔菲研究的见解

2025-06-070
PRE
Characterization of Patients with Lymph Node Only Metastatic Urothelial Carcinoma Treated with Nivolumab Plus Gemcitabine-Cisplatin Versus Gemcitabine-Cisplatin Alone from the CheckMate 901 Trial

CheckMate 901试验中,仅淋巴结转移性尿路上皮癌患者接受纳武利尤单抗联合吉西他滨-顺铂治疗与单独吉西他滨-顺铂治疗的特征分析

2025-05-200
OAAI
Pembrolizumab plus Lenvatinib in patients with metastatic Renal Cell Carcinoma: real-world evidences from the international ARON-1 study

帕博利珠单抗联合仑伐替尼在转移性肾细胞癌患者中的应用:国际ARON-1研究的真实世界证据

2025-05-090
OA
Sex as modifier of survival in patients with advanced urothelial cancer treated with pembrolizumab
2025-03-140
OAAI
Intravesical Administration of Durvalumab for High-risk Non-muscle-invasive Bladder Cancer: A Phase 2 Study by the Hellenic GU Cancer Group

经膀胱给予 durvalumab 治疗高风险非肌层浸润性膀胱癌:Hellenic GU Cancer Group 开展的一项 II 期研究

2025-03-011
PRE
Final Results from SAUL, a Single-arm International Study of Atezolizumab in Unselected Patients with Pretreated Locally Advanced/Metastatic Urinary Tract Carcinoma

SAUL的最终结果,一项阿特珠单抗在未经选择的局部晚期/转移性尿路癌患者中的单臂国际研究

2024-12-011
PRE
Apalutamide in Metastatic Castration-sensitive Prostate Cancer: Results from the Multicenter Real-world ARON-3 Study

阿帕卢他胺在转移性去势敏感前列腺癌中的应用:多中心真实世界ARON-3研究的结果

2024-11-010
OAAI